Cartesian Therapeutics
RNAC
16 hedge funds and large institutions have $105M invested in Cartesian Therapeutics in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
+$26.9M |
| 2 |
O
OrbiMed
New York
|
+$25.8M |
| 3 |
PA
Perceptive Advisors
New York
|
+$6.3M |
| 4 |
JP Morgan Chase
New York
|
+$4.22M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.15M |
Top Sellers
RNAC Hedge Fund Activity: Q2 2016 in Review
16 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2016, worth a combined $105M.
Buyers outnumbered sellers: 16 funds opened new RNAC positions and 0 closed out — a net gain of 16 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Polaris Venture Management Co V, opening a new position worth an estimated $26.9M.
- 16 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $105M of Cartesian Therapeutics stock for Q2 2016.
- 16 funds opened new Cartesian Therapeutics positions in Q2 2016 and 0 closed out, a net change of +16 holders.
- The largest Cartesian Therapeutics buyer in Q2 2016 was Polaris Venture Management Co V, an estimated $26.9M added.
Based on aggregated 13F filings for Q2 2016.